Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $85.85 | Total: $429.25 |
| 1 | 10 | $72.72 | Total: $727.20 |
| 1 | 25 | $61.61 | Total: $1,540.25 |
| 1 | 50 | $52.52 | Total: $2,626.00 |
| 1 | 100 | $45.45 | Total: $4,545.00 |
Overview
Avotaciclib (BEY1107) is a potent, orally active cyclin-dependent kinase 1 (CDK1) inhibitor, suitable for research in locally advanced or metastatic pancreatic cancer.
Chemical Properties
| Molecular Formula | C13H11N7O |
| Molecular Weight | 281.27 |
| CAS Numbers | 1983983-41-0 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | OC1=C(N=C(C=C1)C2=NC(N)=NC=C2)C3=NC(N)=NC=C3 |
Storage and Handling
0C Short Term, -20C Long Term
References
Seufferlein T, et al. Phase I Trials in Pancreatic Cancer. Translational Pancreatic Cancer Research pp 219-232.